Cargando…

Neuropsychiatric disorders in adults undergoing chimeric antigen receptor T cells therapy for aggressive lymphomas and acute lymphoblastic leukemia

OBJECTIVE: To evaluate risk factors for neuropsychiatric disorders (NPD) in recipients of CART therapy. METHODS: Patients ≥ 18 years with acute lymphoblastic leukemia (ALL), and aggressive B-cell lymphomas who received CART in 2018 were evaluated. Patients with and without NPD were compared. RESULTS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Emole, Josephine, Lawal, Odunayo, Lupak, Oleksandra, Rangarajan, Hemalatha, Udo, Itoro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9982636/ https://www.ncbi.nlm.nih.gov/pubmed/36873581 http://dx.doi.org/10.1016/j.lrr.2023.100364

Ejemplares similares

Demographic differences among patients treated with chimeric antigen receptor T‐cell therapy in the United States
por: Emole, Josephine, et al.
Publicado: (2022)

Unexplained pancytopenia in acute myeloid leukemia treatment
por: Ezekwudo, Daniel, et al.
Publicado: (2018)

Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia
por: Tomuleasa, Ciprian, et al.
Publicado: (2018)

Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma
por: Steiner, Raphael E., et al.
Publicado: (2021)

Chimeric antigen receptor T-cell therapy in adults with B-cell acute lymphoblastic leukemia
por: Grover, Punita, et al.
Publicado: (2022)

Successful therapy of chimeric antigen receptor T cells for isolated extramedullary acute lymphoblastic leukemia
por: Li, Xiangqun, et al.
Publicado: (2022)

Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma
por: Khurana, Arushi, et al.
Publicado: (2022)

Cluster of differentiation 19 chimeric antigen receptor T-cell therapy in pediatric acute lymphoblastic leukemia
por: Fu, Zexin, et al.
Publicado: (2020)

Chimeric Antigen Receptor T-Cells in B-Acute Lymphoblastic Leukemia: State of the Art and Future Directions
por: Greenbaum, Uri, et al.
Publicado: (2020)

Advances in the development of chimeric antigen receptor-T-cell therapy in B-cell acute lymphoblastic leukemia
por: Zhang, Xian, et al.
Publicado: (2020)

Efficacy and Safety of Chimeric Antigen Receptor T Cells in Acute Lymphoblastic Leukemia With Post-Transplant Relapse
por: Ding, Lijuan, et al.
Publicado: (2021)

Chimeric antigen receptor T-cells in B-acute lymphoblastic leukemia: history, current situation, and future
por: Muller, Bradley J., et al.
Publicado: (2023)

Pirtobrutinib and venetoclax combination overcomes resistance to targeted and chimeric antigen receptor T-cell therapy in aggressive mantle cell lymphoma
por: Liu, Yang, et al.
Publicado: (2022)

Outcome Prediction in Patients With Large B-cell Lymphoma Undergoing Chimeric Antigen Receptor T-cell Therapy
por: Voltin, Conrad-Amadeus, et al.
Publicado: (2023)

Influence of patient characteristics on chimeric antigen receptor T cell therapy in B-cell acute lymphoblastic leukemia
por: An, Furun, et al.
Publicado: (2020)

Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia
por: Zhang, Cheng, et al.
Publicado: (2022)

The Evolution of Chimeric Antigen Receptor T-Cell Therapy in Children, Adolescents and Young Adults with Acute Lymphoblastic Leukemia
por: Ragoonanan, Dristhi, et al.
Publicado: (2022)

2448 The effect of allopurinol on pediatric patients undergoing maintenance chemotherapy for acute lymphoblastic leukemia or lymphoblastic lymphoma
por: Bhuiyan, Mariam M., et al.
Publicado: (2018)

Treatment of Aggressive T Cell Lymphoblastic Lymphoma/leukemia Using Anti-CD5 CAR T Cells
por: Feng, Jia, et al.
Publicado: (2021)

Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia
por: Wei, Guoqing, et al.
Publicado: (2017)

Biomarkers for Chimeric Antigen Receptor T Cell Therapy in Acute Lymphoblastic Leukemia: Prospects for Personalized Management and Prognostic Prediction
por: Hong, Ruimin, et al.
Publicado: (2021)

Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib
por: Emole, Josephine, et al.
Publicado: (2016)

Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies
por: Chen, Kevin H., et al.
Publicado: (2016)

Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia
por: Myers, G Doug, et al.
Publicado: (2021)

Modern Immunotherapy of Adult B-Lineage Acute Lymphoblastic Leukemia with Monoclonal Antibodies and Chimeric Antigen Receptor Modified T Cells
por: Maino, Elena, et al.
Publicado: (2015)

Infection Complications after Lymphodepletion and Dosing of Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia or B Cell Non-Hodgkin Lymphoma
por: Korell, Felix, et al.
Publicado: (2021)

Aggressive lung involvement in a patient with T‐acute lymphoblastic leukaemia/lymphoblastic lymphoma: a tricky and rare case report
por: Miyaoka, Chika, et al.
Publicado: (2020)

A Review of Chimeric Antigen Receptor T-Cell Therapy for Myeloma and Lymphoma
por: Atrash, Shebli, et al.
Publicado: (2021)

Benefits of Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma
por: Zhou, Wenyujing, et al.
Publicado: (2022)

Case of Myocarditis After Chimeric Antigen Receptor T Cells With Intracardiac Lymphoma
por: Lee, Dae Hyun, et al.
Publicado: (2022)

Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor
por: Chen, K H, et al.
Publicado: (2017)

P1415: CELLULAR DYNAMICS IN RESPONDERS AND NON-RESPONDERS AFTER THE TREATMENT OF PATIENTS WITH AGGRESSIVE B-ZELL LYMPHOMAS WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS
por: Walter Georgi, Thomas, et al.
Publicado: (2023)

Bridging chimeric antigen receptor T-cell before transplantation improves prognosis of relapsed/refractory B-cell acute lymphoblastic leukemia
por: Zhao, Xiangyu, et al.
Publicado: (2023)

Chimeric antigen receptor T-cell therapy for adult B-cell acute lymphoblastic leukemia: state-of-the-(C)ART and the road ahead
por: Pasvolsky, Oren, et al.
Publicado: (2023)

Current and future perspectives of chimeric antigen receptors against glioblastoma
por: Zhang, Josephine, et al.
Publicado: (2022)

Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
por: Gibson, Amber, et al.
Publicado: (2021)

Current Use of Asparaginase in Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
por: Maese, Luke, et al.
Publicado: (2022)

Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL)
por: Tbakhi, Bushra, et al.
Publicado: (2022)

Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma
por: Zhou, Jin, et al.
Publicado: (2022)

Severe bloody diarrhea due to cytokine release syndrome after chimeric antigen receptor T cell therapy for refractory acute lymphoblastic leukemia
por: Shima, Haruko, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ep51o7ievhe6g96ul9msa0svg7